Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies

Antonio Martinez-Frances

doi:doi:10.11648/j.ajim.20210904.13

| Peer-Reviewed

Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies

Antonio Martinez-Frances

Published in American Journal of Internal Medicine (Volume 9, Issue 4)

Received: 16 May 2021 Accepted: 7 June 2021 Published: 9 July 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

An increasing number of prevalent conditions in the adult population associated with absolute or/and functional iron deficiencies (ID) may predispose to iron deficiency anemia (IDA). Oral iron formulations, especially ferrous salts, are generally regarded as the first line therapies for adult-onset ID and IDA according to several current guidelines. However, they have been frequently associated with gastrointestinal side effects, and with a subsequent high treatment discontinuation. Iron protein succinylate (IPS) is an iron complex containing 5% of ferric iron engulfed in a succinylated casein shell that precipitates in acid pH and becomes soluble at neutral to alkaline pH, gradually releasing iron into the intestinal lumen, and, hence, overcoming the gastric and intestinal problems of the ferrous compounds, as well as improving intestinal iron absorption. Besides, IPS has shown to prevent the up regulation of the expression of hepcidin or to induce its expression at a smaller extent when compared with ferrous sulphate (FS). This narrative review addresses the efficacy and safety profiles of IPS for the treatment of ID and IDA in adult patients with a wide range of clinical conditions, such as preoperative and postoperative ID, elderly ID, Chronic Kidney Disease (CKD), Hypothyroidism, regular blood donors, and ID developed in young athletes. In conclusion, IPS compares favorably in efficacy and safety with other currently available oral iron preparations, showing a fast and steady improvement in hematologic parameters (that reflect a better iron absorption), and a lower incidence of adverse events.

Published in	American Journal of Internal Medicine (Volume 9, Issue 4)
DOI	10.11648/j.ajim.20210904.13
Page(s)	171-185
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Iron Deficiency, Iron Deficiency Anemia, Adults, Iron Protein Succinylate, Oral Iron Treatment

References

[1]	Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014; 123 (5): 615-24.
[2]	Camaschella C. Iron-Deficiency Anemia. N Engl J Med. 2015; 373 (5): 485-6.
[3]	Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003; 24 (4 Suppl): S99-103.
[4]	Levi M, Rosselli M, Simonetti M, Brignoli O, Cancian M, Masotti A, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol. 2016; 97 (6): 583-93.
[5]	Burton JK, Yates LC, Whyte L, Fitzsimons E, Stott DJ. New horizons in iron deficiency anaemia in older adults. Age Ageing. 2020.
[6]	Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017; 31 (4): 225-33.
[7]	Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015; 102 (6): 1585-94.
[8]	Santiago P. Ferrous versus Ferric Oral Iron Formulations for the Treatment of Iron Deficiency: A Clinical Overview. The Scientific World Journal. 2012; 2012: 846824.
[9]	Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015; 10 (2): e0117383.
[10]	Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015; 126 (17): 1981-9.
[11]	Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. The Lancet Haematology. 2017; 4 (11): e524-e33.
[12]	Martinez Frances A, Leal Martinez-Bujanda J. Efficacy and tolerability of oral iron protein succinylate: a systematic review of three decades of research. Curr Med Res Opin. 2020: 1-11.
[13]	Urso K, Leal Martínez-Bujanda J, Del Prado JM. Iron Protein Succinylate in the Management of Iron Deficiency Anemia: A Comparative Study with Ferrous Sulphate at Low and High Therapeutic Doses. Nutrients. 2021; 13 (3).
[14]	Camaschella C. Iron deficiency. Blood. 2019; 133 (1): 30-9.
[15]	De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017; 42: 16-23.
[16]	Elstrott B, Khan L, Olson S, Raghunathan V, DeLoughery T, Shatzel JJ. The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol. 2020; 104 (3): 153-61.
[17]	Low MS, Speedy J, Styles CE, De-Regil LM, Pasricha SR. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database Syst Rev. 2016; 4: Cd009747.
[18]	Cable RG, Spencer BR. Iron supplementation by blood donors: demographics, patterns of use, and motivation. Transfusion. 2019; 59 (9): 2857-64.
[19]	Drexler C, Macher S, Lindenau I, Holter M, Moritz M, Stojakovic T, et al. High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial. Clin Nutr. 2020; 39 (3): 737-45.
[20]	Zalpuri S, Schotten N, Baart AM, van de Watering LM, van den Hurk K, van Kraaij MGJ. Iron deficiency-related symptoms in whole blood donors: a systematic review. Transfusion. 2019; 59 (10): 3275-87.
[21]	Coates A, Mountjoy M, Burr J. Incidence of Iron Deficiency and Iron Deficient Anemia in Elite Runners and Triathletes. Clin J Sport Med. 2017; 27 (5): 493-8.
[22]	Pedlar CR, Brugnara C, Bruinvels G, Burden R. Iron balance and iron supplementation for the female athlete: A practical approach. Eur J Sport Sci. 2018; 18 (2): 295-305.
[23]	Rubeor A, Goojha C, Manning J, White J. Does Iron Supplementation Improve Performance in Iron-Deficient Nonanemic Athletes? Sports health. 2018; 10 (5): 400-5.
[24]	Sim M, Garvican-Lewis LA, Cox GR, Govus A, McKay AKA, Stellingwerff T, et al. Iron considerations for the athlete: a narrative review. Eur J Appl Physiol. 2019; 119 (7): 1463-78.
[25]	Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020; 31 (3): 456-68.
[26]	Begum S, Latunde-Dada GO. Anemia of Inflammation with An Emphasis on Chronic Kidney Disease. Nutrients. 2019; 11 (10).
[27]	Collister D, Rigatto C, Tangri N. Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens. 2017; 26 (3): 214-8.
[28]	Murawska N, Fabisiak A, Fichna J. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016; 22 (5): 1198-208.
[29]	Nielsen OH, Soendergaard C, Vikner ME, Weiss G. Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. Nutrients. 2018; 10 (1).
[30]	Girelli D, Marchi G, Camaschella C. Anemia in the Elderly. Hemasphere. 2018; 2 (3): e40.
[31]	Lanier JB, Park JJ, Callahan RC. Anemia in Older Adults. Am Fam Physician. 2018; 98 (7): 437-42.
[32]	García Erce JA, Altés A, López Rubio M, Remacha AF. Management of iron deficiency in various clinical conditions and the role of intravenous iron: Recommendations of the Spanish Erythropathology Group of the Spanish Society of Haematology and Haemotherapy. Revista clinica espanola. 2020; 220 (1): 31-42.
[33]	Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016; 387 (10021): 907-16.
[34]	Danisi M FS. Terapia dell’anemia sideropenica: studio controllato ferritina versus ferroproteinsuccinilato. Riforma Med. 1987; 102: 457-9.
[35]	Gordeuk VR, Brittenham GM, McLaren CE, Hughes MA, Keating LJ. Carbonyl iron therapy for iron deficiency anemia. Blood. 1986; 67 (3): 745-52.
[36]	Cogo R. Comparison of efficacy and tolerability of iron proteinsuccinilate vs. a ferritin compound in iron-deficient patients. Boll Chim Farm. 1988; Suppl. Cli.
[37]	DiSomma C MP, Spiga L, et al. Valutazione comparativa del trattamento con ferroproteinsuccinilato e ferritina. Riforma Medica. 1988; 103: 385-8.
[38]	Ekenved G, Norrby A, Solvell L. Serum iron increase as a measure of iron absorption - studies on the correlation with total absorption. Scand J Haematol Suppl. 1976; 28: 31-49.
[39]	DiGiacomo G DD, D’Antonio S, et al.. Loading Serum Iron Curve and Iron Absoption after the Administration of three different preparations. La Riv Medica Ital 1987; VI: 4–5. 1987.
[40]	Pedrazzoli P, Scotti A, Farina D. Comparison trial of iron succinylprotein complex or iron gluconate complex in the treatment of iron deficiency anemia. Clin Ther. 1988; 10 (4): 414-20.
[41]	Pogliani E SA, Acuto G. Clinical efficacy and tolerability of iron protein succinylate in comparison to slow release iron sulphate in sideropenic anemia. 1990.
[42]	Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1,000 patients. Int J Clin Pharmacol Ther Toxicol. 1993; 31 (3): 103-23.
[43]	KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2012. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf.
[44]	NICE guideline [NG24]. Blood transfusion. https://www.nice.org.uk/guidance/ng24/chapter/Recommendations#alternatives-to-blood-transfusion-for-patients-having-surgery-2.
[45]	Piccoli G. Assessment of the Biological Safety and the Subjective Tolerability of Iron Proteinsuccinylate in Patients with Chronic Renal Failure and Iron Deficiency. 1990.
[46]	Gomez-Ramirez S, Bisbe E, Shander A, Spahn DR, Munoz M. Management of Perioperative Iron Deficiency Anemia. Acta Haematol. 2019; 142 (1): 21-9.
[47]	Abeysiri S, Chau M, Richards T. Perioperative Anemia Management. Semin Thromb Hemost. 2020; 46 (1): 8-16.
[48]	Kotze A, Harris A, Baker C, Iqbal T, Lavies N, Richards T, et al. British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia. Br J Haematol. 2015; 171 (3): 322-31.
[49]	Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol. 2009; 121 (1): 37-41.
[50]	Muñoz M, Acheson AG, Bisbe E, Butcher A, Gómez-Ramírez S, Khalafallah AA, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia. 2018; 73 (11): 1418-31.
[51]	Ambrosini A. [The activity and tolerability of ferroproteinsuccinylate in the treatment of iron deficiency in surgery]. Bollettino chimico farmaceutico. 1988; 127 (3): 40s-3s.
[52]	Manfredi B, Finelli F. [A new therapeutic approach to iron deficiency]. La Clinica terapeutica. 1987; 123 (1): 25-39.
[53]	Veneroni G CS, Tripodi S, et al. Studio clinico controllato in doppio cieco sull’efficacia terapeutica e sulla tollerabilità di un nuovo prodotto a base di ferro organico. Policlin Sez Med 1996; 103: 21–9.
[54]	Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004; 104 (8): 2263-8.
[55]	Patel KV. Epidemiology of anemia in older adults. Semin Hematol. 2008; 45 (4): 210-7.
[56]	Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016; 127 (23): 2809-13.
[57]	Busti F, Campostrini N, Martinelli N, Girelli D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front Pharmacol. 2014; 5: 83.
[58]	Gruppo Italiano di Studio sulla Sideropenia nell’Anziano. La carenza mariziale nella popolazione anziana instituzionalizzata: indicatori precoci e trattamento farmacologico con ferroproteinsuccinilato. G Gerontol. 1992; 40.
[59]	Ravanbod M, Asadipooya K, Kalantarhormozi M, Nabipour I, Omrani GR. Treatment of iron-deficiency anemia in patients with subclinical hypothyroidism. The American journal of medicine. 2013; 126 (5): 420-4.
[60]	Soliman AT, De Sanctis V, Yassin M, Wagdy M, Soliman N. Chronic anemia and thyroid function. Acta bio-medica: Atenei Parmensis. 2017; 88 (1): 119-27.
[61]	Szczepanek-Parulska E, Hernik A, Ruchala M. Anemia in thyroid diseases. Polish archives of internal medicine. 2017; 127 (5): 352-60.
[62]	Duntas LH, Krassas GE, Mantzou E, Koutras DA. Effectiveness of Combined Treatment with L-Thyroxine and Iron Proteinsuccinylate in Patients with Subclinical Hypothyroidism and Manifested Sideropenic Anemia. Nutritional Neuroscience. 2000; 3 (6): 407-14.
[63]	Spencer BR. Iron Depletion in Adult and Teenage Blood Donors: Prevalence, Clinical Impact, and Options for Mitigation. Hematol Oncol Clin North Am. 2019; 33 (5): 781-96.
[64]	Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spencer BR, et al. Effect of iron supplementation on iron stores and total body iron after whole blood donation. Transfusion. 2016; 56 (8): 2005-12.
[65]	Landucci G, Frontespezi S. Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. The Journal of international medical research. 1987; 15 (6): 379-82.
[66]	Burden RJ, Morton K, Richards T, Whyte GP, Pedlar CR. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis. British journal of sports medicine. 2015; 49 (21): 1389-97.
[67]	Trojachanec Z. Sport Anemia and Sports Results.
[68]	Cordova A, Mielgo-Ayuso J, Fernandez-Lazaro CI, Caballero-Garcia A, Roche E, Fernandez-Lazaro D. Effect of Iron Supplementation on the Modulation of Iron Metabolism, Muscle Damage Biomarkers and Cortisol in Professional Cyclists. Nutrients. 2019; 11 (3).
[69]	DeLoughery TG. Safety of Oral and Intravenous Iron. Acta Haematol. 2019; 142 (1): 8-12.
[70]	Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol. 2010; 16 (22): 2720-5.
[71]	Cremonesi P, Caramazza I. Chemical and biological characterization of iron-protein succinylate (ITF 282). Int J Clin Pharmacol Ther Toxicol. 1993; 31 (1): 40-51.
[72]	Raja KB, Jafri SE, Dickson D, Acebron A, Cremonesi P, Fossati G, et al. Involvement of iron (ferric) reduction in the iron absorption mechanism of a trivalent iron-protein complex (iron protein succinylate). Pharmacol Toxicol. 2000; 87 (3): 108-15.
[73]	Cogo R, De Luca P, Mastrantoni M. Evaluation of the siderohaemic curve after loading administration of iron--protein--succinylate to gastrectomized subjects: a controlled study. The Journal of international medical research. 1990; 18 (3): 225-7.
[74]	Danisi M, Guerresi E, Landucci G, Gori G, Ceccarelli G. Serum iron concentrations following administration of two different iron preparations. J Int Med Res. 1987; 15 (6): 374-8.
[75]	Cogo R. [Comparison of the efficacy and tolerability of ferroproteinsuccinylate and ferritin preparations in iron deficiency in general medicine]. Bollettino chimico farmaceutico. 1988; 127 (3): 25s-9s.
[76]	Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease. Acta Haematol. 2019; 142 (1): 44-50.
[77]	Gómez Ramírez S, Remacha Sevilla ÁF, Muñoz Gómez M. Anaemia in the elderly. Medicina Clínica (English Edition). 2017; 149 (11): 496-503.
[78]	Kopcke W, Sauerland MC. Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity. Arzneimittelforschung. 1995; 45 (11): 1211-6.

Cite This Article

Plain Text BibTeX RIS

APA Style

Antonio Martinez-Frances. (2021). Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. American Journal of Internal Medicine, 9(4), 171-185. https://doi.org/10.11648/j.ajim.20210904.13

Copy | Download

ACS Style

Antonio Martinez-Frances. Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. Am. J. Intern. Med. 2021, 9(4), 171-185. doi: 10.11648/j.ajim.20210904.13

Copy | Download

AMA Style

Antonio Martinez-Frances. Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. Am J Intern Med. 2021;9(4):171-185. doi: 10.11648/j.ajim.20210904.13

Copy | Download

@article{10.11648/j.ajim.20210904.13,
  author = {Antonio Martinez-Frances},
  title = {Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {4},
  pages = {171-185},
  doi = {10.11648/j.ajim.20210904.13},
  url = {https://doi.org/10.11648/j.ajim.20210904.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210904.13},
  abstract = {An increasing number of prevalent conditions in the adult population associated with absolute or/and functional iron deficiencies (ID) may predispose to iron deficiency anemia (IDA). Oral iron formulations, especially ferrous salts, are generally regarded as the first line therapies for adult-onset ID and IDA according to several current guidelines. However, they have been frequently associated with gastrointestinal side effects, and with a subsequent high treatment discontinuation. Iron protein succinylate (IPS) is an iron complex containing 5% of ferric iron engulfed in a succinylated casein shell that precipitates in acid pH and becomes soluble at neutral to alkaline pH, gradually releasing iron into the intestinal lumen, and, hence, overcoming the gastric and intestinal problems of the ferrous compounds, as well as improving intestinal iron absorption. Besides, IPS has shown to prevent the up regulation of the expression of hepcidin or to induce its expression at a smaller extent when compared with ferrous sulphate (FS). This narrative review addresses the efficacy and safety profiles of IPS for the treatment of ID and IDA in adult patients with a wide range of clinical conditions, such as preoperative and postoperative ID, elderly ID, Chronic Kidney Disease (CKD), Hypothyroidism, regular blood donors, and ID developed in young athletes. In conclusion, IPS compares favorably in efficacy and safety with other currently available oral iron preparations, showing a fast and steady improvement in hematologic parameters (that reflect a better iron absorption), and a lower incidence of adverse events.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies
AU  - Antonio Martinez-Frances
Y1  - 2021/07/09
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210904.13
DO  - 10.11648/j.ajim.20210904.13
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 171
EP  - 185
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210904.13
AB  - An increasing number of prevalent conditions in the adult population associated with absolute or/and functional iron deficiencies (ID) may predispose to iron deficiency anemia (IDA). Oral iron formulations, especially ferrous salts, are generally regarded as the first line therapies for adult-onset ID and IDA according to several current guidelines. However, they have been frequently associated with gastrointestinal side effects, and with a subsequent high treatment discontinuation. Iron protein succinylate (IPS) is an iron complex containing 5% of ferric iron engulfed in a succinylated casein shell that precipitates in acid pH and becomes soluble at neutral to alkaline pH, gradually releasing iron into the intestinal lumen, and, hence, overcoming the gastric and intestinal problems of the ferrous compounds, as well as improving intestinal iron absorption. Besides, IPS has shown to prevent the up regulation of the expression of hepcidin or to induce its expression at a smaller extent when compared with ferrous sulphate (FS). This narrative review addresses the efficacy and safety profiles of IPS for the treatment of ID and IDA in adult patients with a wide range of clinical conditions, such as preoperative and postoperative ID, elderly ID, Chronic Kidney Disease (CKD), Hypothyroidism, regular blood donors, and ID developed in young athletes. In conclusion, IPS compares favorably in efficacy and safety with other currently available oral iron preparations, showing a fast and steady improvement in hematologic parameters (that reflect a better iron absorption), and a lower incidence of adverse events.
VL  - 9
IS  - 4
ER  -

Copy | Download

Author Information

Antonio Martinez-Frances

Haematology Department, University Hospital of Santa Lucia, Cartagena, Spain

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Antonio Martinez-Frances. (2021). Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. American Journal of Internal Medicine, 9(4), 171-185. https://doi.org/10.11648/j.ajim.20210904.13

Copy | Download

ACS Style

Antonio Martinez-Frances. Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. Am. J. Intern. Med. 2021, 9(4), 171-185. doi: 10.11648/j.ajim.20210904.13

Copy | Download

AMA Style

Antonio Martinez-Frances. Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies. Am J Intern Med. 2021;9(4):171-185. doi: 10.11648/j.ajim.20210904.13

Copy | Download

@article{10.11648/j.ajim.20210904.13,
  author = {Antonio Martinez-Frances},
  title = {Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies},
  journal = {American Journal of Internal Medicine},
  volume = {9},
  number = {4},
  pages = {171-185},
  doi = {10.11648/j.ajim.20210904.13},
  url = {https://doi.org/10.11648/j.ajim.20210904.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20210904.13},
  abstract = {An increasing number of prevalent conditions in the adult population associated with absolute or/and functional iron deficiencies (ID) may predispose to iron deficiency anemia (IDA). Oral iron formulations, especially ferrous salts, are generally regarded as the first line therapies for adult-onset ID and IDA according to several current guidelines. However, they have been frequently associated with gastrointestinal side effects, and with a subsequent high treatment discontinuation. Iron protein succinylate (IPS) is an iron complex containing 5% of ferric iron engulfed in a succinylated casein shell that precipitates in acid pH and becomes soluble at neutral to alkaline pH, gradually releasing iron into the intestinal lumen, and, hence, overcoming the gastric and intestinal problems of the ferrous compounds, as well as improving intestinal iron absorption. Besides, IPS has shown to prevent the up regulation of the expression of hepcidin or to induce its expression at a smaller extent when compared with ferrous sulphate (FS). This narrative review addresses the efficacy and safety profiles of IPS for the treatment of ID and IDA in adult patients with a wide range of clinical conditions, such as preoperative and postoperative ID, elderly ID, Chronic Kidney Disease (CKD), Hypothyroidism, regular blood donors, and ID developed in young athletes. In conclusion, IPS compares favorably in efficacy and safety with other currently available oral iron preparations, showing a fast and steady improvement in hematologic parameters (that reflect a better iron absorption), and a lower incidence of adverse events.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Efficacy and Tolerability of Oral Iron Protein Succinylate in the Treatment of Iron Deficiency Anemia in Adults with Diverse Pathologies
AU  - Antonio Martinez-Frances
Y1  - 2021/07/09
PY  - 2021
N1  - https://doi.org/10.11648/j.ajim.20210904.13
DO  - 10.11648/j.ajim.20210904.13
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 171
EP  - 185
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20210904.13
AB  - An increasing number of prevalent conditions in the adult population associated with absolute or/and functional iron deficiencies (ID) may predispose to iron deficiency anemia (IDA). Oral iron formulations, especially ferrous salts, are generally regarded as the first line therapies for adult-onset ID and IDA according to several current guidelines. However, they have been frequently associated with gastrointestinal side effects, and with a subsequent high treatment discontinuation. Iron protein succinylate (IPS) is an iron complex containing 5% of ferric iron engulfed in a succinylated casein shell that precipitates in acid pH and becomes soluble at neutral to alkaline pH, gradually releasing iron into the intestinal lumen, and, hence, overcoming the gastric and intestinal problems of the ferrous compounds, as well as improving intestinal iron absorption. Besides, IPS has shown to prevent the up regulation of the expression of hepcidin or to induce its expression at a smaller extent when compared with ferrous sulphate (FS). This narrative review addresses the efficacy and safety profiles of IPS for the treatment of ID and IDA in adult patients with a wide range of clinical conditions, such as preoperative and postoperative ID, elderly ID, Chronic Kidney Disease (CKD), Hypothyroidism, regular blood donors, and ID developed in young athletes. In conclusion, IPS compares favorably in efficacy and safety with other currently available oral iron preparations, showing a fast and steady improvement in hematologic parameters (that reflect a better iron absorption), and a lower incidence of adverse events.
VL  - 9
IS  - 4
ER  -

Copy | Download